Lymphoma (includes NHL, HL, CNS Lymphoma)

Zanubrutinib Granted Breakthrough Designation for Mantle Cell Lymphoma

(Curetoday.com) Jan 15, 2019 - The Food and Drug Administration (FDA) has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one prior therapy, according to BeiGene, the company manufacturing the agent.

read article

Liver Transplant Patients Have Higher Prevalence of Colon Cancer and Non-Hodgkin Lymphoma

(Loyola University Medical Center) Jan 10, 2019 - Liver transplant patients over time experience an increasing trend toward colon cancer and non-Hodgkin lymphoma, according to an award-winning study led by a Loyola Medicine gastroenterologist.

read press release

miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen

(NASDAQ) Jan 10, 2019 - miRagen Therapeutics, Inc. today announced data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in cutaneous T-cell lymphoma (CTCL) and in adult T-cell leukemia/lymphoma (ATLL). The Company will also discuss initial clinical experience in treating diffuse large B-cell lymphoma (DLBCL) patients with cobomarsen.

read article

Moderna Stock Pops 4.2% on Clinical Update

(BioSpace) Jan 9, 2019 - Moderna’s clinical and business update at the JP Morgan Healthcare Conference led the newly public company shares to pop 4.2 percent, a welcome change.

read article

Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives

(Moderna) Jan 8, 2019 - Moderna, Inc. today announced recent updates to several of its immuno-oncology and rare disease programs and outlined its 2019-2020 corporate objectives.

read corporate press release

Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance

(Epizyme) Jan 4, 2019 - Epizyme, Inc. today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations.

read corporate press release

Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305

(MarketWatch) Dec 21, 2018 - Loxo Oncology, Inc. today announced that it has initiated a Phase 1/2 clinical trial of LOXO-305.

read article

Survivors of Childhood Hodgkin Lymphoma Face High Long-Term Risk of Solid Cancers

(Wiley) Dec 17, 2018 - New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later.

read press release

NICE Gives Final Seal of Approval For Gilead’s CAR-T in NHL

(Pharmaphorum [UK]) Dec 7, 2018 - NICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with aggressive forms of non-Hodgkin lymphoma.

read article

3 Questions Leaving ASH

(BioPharma Dive) Dec 5, 2018 - Like many a medical meeting, ASH showcased data that — while promising — also offers as many questions as answers. With another American Society of Hematology meeting in the books, the industry can take a minute to appreciate the notable advances seen in San Diego earlier this week. A new collection of medicines look ready to take on multiple myeloma, while CAR-T and gene therapies affirmed their emerging place in the treatment of blood illnesses.

read article

Biosimilar Beats Subcutaneous Rituximab on Cost Savings in NHL

(The Center For Biosimilars) Dec 5, 2018 - The launch of biosimilar rituximab is an eagerly awaited event among US healthcare stakeholders who are cognizant of the high cost of intravenously (IV) administered rituximab in treating non-Hodgkin lymphoma (NHL). At the same time, another innovation in rituximab delivery—a subcutaneously administered rituximab formulation—has the potential to save both cost and time.

read article

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

(MarketWatch) Dec 3, 2018 - Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced that data from the ECHELON-2 phase 3 clinical trial will be presented today in an oral session at the 60[th] American Society of Hematology (ASH) Annual Meeting. The data demonstrated that frontline treatment with ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) is effective in extending progression-free survival (PFS) and overall survival (OS) with a safety profile comparable to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), a current standard of care in patients with CD30-expressing peripheral T-cell lymphomas (PTCL). These data were also simultaneously published online in The Lancet. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL.

read article

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

(ASH) Dec 4, 2018 - Three studies being presented today during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego offer more targeted solutions for managing CLL and multiple myeloma. “The most important take home point is that all three of these late-breaking studies demonstrate how targeted therapies are improving outcomes for our patients,” said press briefing moderator Aaron Gerds, MD, MS, of the Cleveland Clinic Taussig Cancer Institute. “For both multiple myeloma and chronic lymphocytic leukemia, we’re rapidly shifting from cytotoxic to targeted treatments, which is exciting given the toxicities patients can experience with traditional chemotherapy.”

read press release

ASH: Seattle Genetics, Takeda Show off Data That Secured Latest FDA Approval for Adcetris

(BioSpace) Dec 4, 2018 - Less than one month after Seattle Genetics grabbed approval from the U.S. Food and Drug Administration (FDA) for Adcetris as a therapy for previously untreated systemic anaplastic large cell lymphoma, the company showed off the data that earned that nod at ASH.

read article

New Phase 3 Study Findings Show IMBRUVICA® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia

(J&J) Dec 4, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the National Cancer Institute (NCI)-sponsored Phase 3 study (E1912) led by the ECOG-ACRIN Research Group (ECOG-ACRIN) evaluating IMBRUVICA® (ibrutinib) plus rituximab compared to a chemotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) in previously untreated patients aged 70 years or younger with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

read corporate press release

IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

(J&J) Dec 3, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 iLLUMINATE (PCYC-1130) study, which showed the combination of IMBRUVICA® (ibrutinib) plus obinutuzumab significantly improved progression-free survival (PFS) versus chlorambucil plus obinutuzumab in patients with newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the most common form of leukemia in adults.

read corporate press release

Celltrion Healthcare Presents Positive Results For CT-P10, Biosimilar Rituximab, In Advanced Follicular Lymphoma At The American Society of Hematology Meeting 2018

(AP) Dec 4, 2018 - Celltrion Healthcare today presented new data at the American Society of Hematology Meeting (ASH) 2018, which shows that the efficacy and safety of CT-P10 is comparable to reference rituximab in patients with advanced follicular lymphoma (AFL) over two years.

read article

Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies

(Seeking Alpha) Dec 3, 2018 - Portola Pharmaceuticals, Inc.® today announced updated interim results from the Company’s ongoing Phase 2a study of cerdulatinib, an investigational, oral Syk/JAK inhibitor, in patients with specific subtypes of T-cell Non-Hodgkin Lymphoma, including relapsed/refractory peripheral T-cell lymphoma (PTCL); angioimmunoblastic T-cell lymphoma (AITL), a subset of PTCL; and cutaneous T-cell lymphoma (CTCL).

read article

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

(Morningstar) Dec 2, 2018 - Celgene Corporation today announced results of the phase 3 AUGMENT study, which showed that REVLIMID® (lenalidomide) in combination with rituximab (R2) demonstrated superior progression-free survival (PFS) in patients with relapsed/refractory indolent lymphoma compared to patients who received rituximab plus placebo (R-placebo).

read article

ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On

(Xconomy National) Dec 3, 2018 - Last week, Xconomy previewed the American Society of Hematology’s big meeting in San Diego, the largest medical gathering in the country on blood diseases. We took a deep dive into five specific disease areas under scrutiny, from lymphoma to hemophilia to sickle cell disease and more. News related to those diseases and others have already caused biotech stocks to shoot up and down during the first few days of the meeting, which concludes Wednesday. Today we’re spotlighting a few of the companies that have seen their shares rise or fall with new results.

read article
Next Page